Related Experiment Video
Updated: Jul 29, 2025

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
Published on: January 27, 2013
Targeting the inward rectifier potassium channel 5.1 in thyroid cancer: artificial intelligence-facilitated molecular
Xue Yang1,2,3, Yonglin Wu1,2,3, Shaojie Xu1,2,3
1Department of Thyroid and Breast Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Background:
Recurrent and metastatic thyroid cancer is more invasive and can transform to dedifferentiated thyroid cancer, thus leading to a severe decline in the 10-year survival. The thyroid-stimulating hormone receptor (TSHR) plays an important role in differentiation process. We aim to find a therapeutic target in redifferentiation strategies for thyroid cancer.
Methods:
Our study integrated the differentially expressed genes acquired from the Gene Expression Omnibus database by comparing TSHR expression levels in the Cancer Genome Atlas database. We conducted functional enrichment analysis and verified the expression of these genes by RT-PCR in 68 pairs of thyroid tumor and paratumor tissues. Artificial intelligence-enabled virtual screening was combined with the VirtualFlow platform for deep docking.
Results:
We identified five genes (KCNJ16, SLC26A4, TG, TPO, and SYT1) as potential cancer treatment targets. TSHR and KCNJ16 were downregulated in the thyroid tumor tissues, compared with paired normal tissues. In addition, KCNJ16 was lower in the vascular/capsular invasion group. Enrichment analyses revealed that KCNJ16 may play a significant role in cell growth and differentiation. The inward rectifier potassium channel 5.1 (Kir5.1, encoded by KCNJ16) emerged as an interesting target in thyroid cancer. Artificial intelligence-facilitated molecular docking identified Z2087256678_2, Z2211139111_1, Z2211139111_2, and PV-000592319198_1 (-7.3 kcal/mol) as the most potent commercially available molecular targeting Kir5.1.
Conclusion:
This study may provide greater insights into the differentiation features associated with TSHR expression in thyroid cancer, and Kir5.1 may be a potential therapeutic target in the redifferentiation strategies for recurrent and metastatic thyroid cancer.
Insights
Thyroid cancer redifferentiation strategies may target Kir5.1 (KCNJ16), a gene downregulated in tumors. This study identifies Kir5.1 as a potential therapeutic target for recurrent and metastatic thyroid cancer.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Recurrent and metastatic thyroid cancer presents aggressive characteristics, including dedifferentiation, significantly reducing survival rates.
- The thyroid-stimulating hormone receptor (TSHR) is crucial for thyroid cell differentiation.
- Identifying novel therapeutic targets is essential for improving outcomes in advanced thyroid cancer.
Purpose of the Study:
- To identify potential therapeutic targets for thyroid cancer redifferentiation strategies.
- To investigate the role of TSHR in thyroid cancer differentiation.
- To explore novel therapeutic avenues for recurrent and metastatic thyroid cancer.
Main Methods:
- Integrated gene expression data from public databases (GEO, TCGA) to identify differentially expressed genes related to TSHR.
- Performed functional enrichment analysis and validated gene expression using RT-PCR in patient tissues.
- Utilized AI-enabled virtual screening and molecular docking (VirtualFlow) to identify potential drug candidates targeting identified genes.
Main Results:
- Identified five key genes (KCNJ16, SLC26A4, TG, TPO, SYT1) as potential therapeutic targets.
- Found significant downregulation of TSHR and KCNJ16 in thyroid tumor tissues compared to normal tissues.
- KCNJ16 (encoding Kir5.1) showed reduced expression in invasive tumors and is implicated in cell growth and differentiation; AI docking identified potent Kir5.1 inhibitors.
Conclusions:
- Kir5.1 (KCNJ16) is a promising therapeutic target for redifferentiation strategies in recurrent and metastatic thyroid cancer.
- This research provides insights into TSHR's role in thyroid cancer differentiation.
- The identified Kir5.1 targeting molecules warrant further investigation for clinical application.
Related Concept Videos
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Ligand-Gated Ion Channel Receptor: Gating Mechanism
Patch Clamp
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...

